TNFRSF10B pAb detects endogenous levels of TNFRSF10B protein.
Applications
WB, IHC
Reactivity
Human
Immunogen
Recombinant full length Human TNFRSF10B.
Host
Rabbit
Clonality
Polyclonal
Conjugate
Unconjugated
Molecular Weight
~ 48 kDa
Purity
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Recombinant humanized monoclonal antibody to DR5 for use as a research grade Tigatuzumab biosimilar for ELISA, Flow Cytometry, Functional Studies and in vivo Research.
Recombinant human monoclonal antibody to DR5 for use as a research grade Lexatumumab biosimilar for ELISA, Flow Cytometry, Functional Studies and in vivo Research.
Recombinant human monoclonal antibody to DR5 for use as a research grade Conatumumab biosimilar for ELISA, Flow Cytometry, Functional Studies and in vivo Research.
Recombinant human monoclonal antibody to DR5 for use as a research grade Drozitumab biosimilar for ELISA, Flow Cytometry, Functional Studies and in vivo Research.
Recombinant humanized monoclonal antibody to DR5 for use as a research grade Benufutamab biosimilar for ELISA, Flow Cytometry, Functional Studies and in vivo Research.
Recombinant humanized monoclonal antibody to DR5 for use as a research grade Tigatuzumab biosimilar for ELISA, Flow Cytometry, Functional Studies and in vivo Research.
Recombinant human monoclonal antibody to DR5 for use as a research grade Lexatumumab biosimilar for ELISA, Flow Cytometry, Functional Studies and in vivo Research.
Recombinant human monoclonal antibody to DR5 for use as a research grade Conatumumab biosimilar for ELISA, Flow Cytometry, Functional Studies and in vivo Research.
Recombinant human monoclonal antibody to DR5 for use as a research grade Drozitumab biosimilar for ELISA, Flow Cytometry, Functional Studies and in vivo Research.
Recombinant humanized monoclonal antibody to DR5 for use as a research grade Benufutamab biosimilar for ELISA, Flow Cytometry, Functional Studies and in vivo Research.
